Binci, Perez - Apparato Digerente

•Download as PPTX, PDF•

0 likes•349 views

Questo è il nostro lavoro sull'apparato digerente e il morbo di Crohn. Purtroppo qui le GIF non funzionano, se vuole vederle può aprire la presentazione su Google Presentazioni.

Science

Apparato digerente
Binci Alessia, Perez Virginia

Struttura
1- Esofago
2- Stomaco
3- Fegato
4- Cistifellea
5- Pancreas
6- Intestino tenue
7- Intestino crasso
8- Appendice

https://www.youtube.com/watch?v=Yy_UCjqql4o
Video sul funzionamento dell’apparato digerente

Cos’è
Malattia infiammatoria cronica
dell’intestino

Grazie per l’attenzione
Binci Alessia, Perez Virginia
3°AL
A.S. 2016/2017

Infliximab is a chimeric monoclonal antibody used to treat various autoimmune diseases by binding to and inhibiting tumor necrosis factor-alpha (TNF-α), a key part of the autoimmune response. It was originally developed as a mouse antibody but was modified to contain mostly human antibody sequences. Infliximab is administered via intravenous infusion every 6-8 weeks and is approved by the FDA to treat Crohn's disease, ulcerative colitis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis.

de Matthaeis Marina. Patologia del canale analeGianfranco Tammaro

Mici, Emilio Gentile Warschauer, infiammatorie croniche intestino, Crohn, ret...

Gentile Warschauer Emilio

Remicade(Infliximab) presentation

Sanjida Sultana

Remicade, also known as Infliximab, is a prescription drug administered via intravenous infusion to treat immune system diseases like Crohn's disease, rheumatoid arthritis, and ulcerative colitis. It works by binding to and blocking tumor necrosis factor alpha, which contributes to inflammation. Common side effects include stomach/chest pain and infections, while serious risks include tuberculosis, cancer, and heart failure. The drug requires careful dosage and administration in a medical setting due to its potential side effects.

Apparato digerente Nadia

benadia

Apparato digerenteMaura Bracaloni

Crohn's disease pharmascape cv

Oliver Vit

1) Remicade, Humira, Tysabri, and Cimzia are the main biologics approved for treating Crohn's disease. 2) Remicade and Humira have the longest history and largest safety databases, while Tysabri carries a risk of rare but serious side effects like PML. 3) The document provides brief summaries of each drug's mechanism of action, clinical trial results demonstrating efficacy in Crohn's, and safety profiles.

Adalimumab in Pediatric Crohn's Disease

mjavan2001

Humira

Lara Alijarde

Humira es un medicamento biológico comúnmente recetado para el tratamiento de la psoriasis moderada a grave. Si bien puede ser efectivo, Humira también conlleva riesgos significativos como infecciones graves e incrementos en ciertos tipos de cáncer. El documento también discute alternativas de tratamiento como la terapia PUVA que pueden presentar un mejor balance de riesgos y beneficios para algunos pacientes.

disbiosi, emorroidi, stipsi e sindrome da ostruita defecazione

Andrea Favara